Validation of epistaxis severity score for hereditary hemorrhagic telangiectasia in Japan
Validation of epistaxis severity score for hereditary hemorrhagic telangiectasia in Japan
复制标题
日本遗传性出血性毛细血管扩张症鼻出血严重程度评分的验证
DOI：
10.1016/j.anl.2021.11.005
复制
发表时间：
2022
影响因子：
1.7
通讯作者：
Inohara Hidenori
中科院分区：
文献类型：
--
作者：
Hayama Masaki;Maeda Yohei;Shikina Takashi;Tatehara Shun;Inokuchi Go;Hoag Jeffrey B;Sato Tomoharu;Obata Sho;Nakatani Ayaka;Amano Yuta;Hida Eisuke;Nibu Ken-Ichi;Inohara Hidenori
本研究旨在评估与健康相关的生活质量（HR-QoL）的遗传性出血性毛细血管扩张症（HHT）的患者，强调的作用/社会方面，并验证这些patients.MethodsThe日本版的鼻出血严重程度评分（ESS）创建通过正向和反向翻译，并与原作者协商。通过比较ESS严重程度与既往鼻出血治疗的侵袭性并评估ESS与HR-QoL之间的相关性进行验证分析。病史表、ESS问卷和医学结局研究简表36（SF-36）于2020年8月分发给HHT受试者。ESS和SF-36总分之间的关系进行方差分析和斯皮尔曼的correlation.ResultsIn总数，73名参与者被纳入本研究。平均ESS为5.02;有轻度（32.9%），中度（45.2%）和重度（21.9%）鼻出血组。具有较高ESS的患者接受显著更侵入性的治疗（Fisher精确检验，p< 0.05）。ESS评分与躯体健康评分（PCS）呈负相关（r=-0.489，p < 0.001）。肝脏和胃肠道动静脉畸形共病显著降低PCS（p< 0.05）。多元回归分析显示ESS是一个显著变量（p< 0.01）。的作用/社会成分得分显着降低，在严重的ESS组比在轻度或中度group.ConclusionThe日本版的ESS被认为是有效的，并可能是有用的，作为未来的HHT相关的鼻出血试验在日本的结果衡量。
ObjectiveThis study aimed to assess the health-related QoL (HR-QoL) of patients with hereditary hemorrhagic telangiectasia (HHT), with emphasis on the role/social aspects, and validate the Japanese version of the epistaxis severity score (ESS) in these patients.MethodsThe Japanese version of the ESS was created through forward and reverse translation, and consultation with the original author. A validation analysis was performed by comparing ESS severity with the invasiveness of previous treatments for epistaxis and assessing the correlation between the ESS and HR-QoL. Medical history forms, ESS questionnaires, and the Medical Outcomes Study Short Form 36 (SF-36) were distributed to participants with HHT in August 2020. The relation between the ESS and summary scores of SF-36 was assessed by performing analysis of variance and Spearman's correlation.ResultsIn total, 73 participants were included in this study. The average ESS was 5.02; there were mild (32.9%), moderate (45.2%), and severe (21.9%) epistaxis groups. Patients with higher ESS received a significantly more invasive treatment (Fisher's exact test,p< 0.05). The ESS was also negatively correlated with the physical component score (PCS) (r= -0.489,p< 0.001). Comorbid liver and gastrointestinal arteriovenous malformations significantly reduced the PCS (p< 0.05). Multiple regression analysis revealed that the ESS was a significant variable (p< 0.01). The role/social component score was significantly lower in the severe ESS group than in the mild or moderate group.ConclusionThe Japanese version of the ESS was considered valid and may be useful as an outcome measure of future HHT-associated epistaxis trials in Japan.